GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biophytis SA (OTCPK:BPTSY) » Definitions » Total Liabilities

Biophytis (Biophytis) Total Liabilities : $17.28 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Biophytis Total Liabilities?

Biophytis's Total Liabilities for the quarter that ended in Dec. 2023 was $17.28 Mil.

Biophytis's quarterly Total Liabilities declined from Dec. 2022 ($25.32 Mil) to Jun. 2023 ($19.47 Mil) and declined from Jun. 2023 ($19.47 Mil) to Dec. 2023 ($17.28 Mil).

Biophytis's annual Total Liabilities declined from Dec. 2021 ($32.85 Mil) to Dec. 2022 ($25.32 Mil) and declined from Dec. 2022 ($25.32 Mil) to Dec. 2023 ($17.28 Mil).


Biophytis Total Liabilities Historical Data

The historical data trend for Biophytis's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biophytis Total Liabilities Chart

Biophytis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.84 30.34 32.85 25.32 17.28

Biophytis Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.85 32.69 25.32 19.47 17.28

Biophytis Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biophytis's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.484+(2.793+0.749
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.258)
=17.28

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=13.043--4.241
=17.28

Biophytis's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.484+(2.793+0.749
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.258)
=17.28

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=13.043--4.241
=17.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biophytis Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biophytis's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Biophytis (Biophytis) Business Description

Traded in Other Exchanges
Address
BC 9, Batiment A 4eme etage, 4 pace Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.